Tango Therapeutics Inc (TNGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.32B
Last updated: Nov 17, 2026 at 11:06 AM ET
Tango Therapeutics Inc (TNGX) Financials: Revenue, Profit and Cash Flow
Tango Therapeutics reported revenue of $62.38M for the fiscal year ended Dec 31, 2025, up 48.3% from the year before. That year, net income was -$101.59M with a net margin of -162.9%, operating cash flow was -$138.89M and free cash flow was -$139.93M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$68.39M.
Revenue and Margins
Over the 6 years to Dec 2025, revenue grew from $24.65M, a compound annual rate of 16.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $62.38M | +48.3% | 100.0% | -178.4% | -162.9% |
| Dec 2024 | $42.07M | +15.2% | 100.0% | -346.1% | -309.7% |
| Dec 2023 | $36.53M | +46.9% | 100.0% | -312.6% | -278.5% |
| Dec 2022 | $24.86M | -32.9% | 100.0% | -446.8% | -435.1% |
| Dec 2021 | $37.04M | +383.8% | 100.0% | -157.1% | -157.2% |
| Dec 2020 | $7.66M | -68.9% | 100.0% | -681.8% | -678.8% |
| Dec 2019 | $24.65M | N/A | -30.9% | -61.5% | -57.2% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $62.38M | $42.07M | $36.53M | $24.86M | $37.04M | $7.66M | $24.65M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $32.27M |
| Gross profit | $62.38M | $42.07M | $36.53M | $24.86M | $37.04M | $7.66M | -$7.63M |
| Research and development | $132.16M | $143.92M | $115.20M | $105.91M | $77.64M | $49.99M | $32.27M |
| Operating income | -$111.29M | -$145.59M | -$114.17M | -$111.07M | -$58.19M | -$52.20M | -$15.16M |
| Net income | -$101.59M | -$130.30M | -$101.74M | -$108.18M | -$58.23M | -$51.97M | -$14.10M |
| EBITDA | -$104.94M | -$135.49M | -$105.81M | -$107.97M | -$57.54M | -$51.36M | -$14.52M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $53.81M | $3.18M | $5.39M | $4.12M | $11.61M | $19.88M | $6.47M | $5.43M |
| Gross profit | $0 | $0 | $0 | -$479.00K | $53.81M | $3.18M | $5.39M | $4.12M | $11.61M | $19.88M | $6.47M | $5.43M |
| Operating income | -$78.12M | -$59.78M | -$48.77M | -$41.86M | $14.07M | -$40.97M | -$42.53M | -$40.91M | -$32.88M | -$29.55M | -$42.26M | -$35.01M |
| Net income | -$68.39M | -$55.34M | -$45.51M | -$38.75M | $15.88M | -$38.85M | -$39.88M | -$37.67M | -$29.17M | -$25.55M | -$37.91M | -$30.76M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $2.74M by $109.54M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $398.69M | $316.49M | $402.57M | $436.47M | $500.15M | $207.25M | $55.76M |
| Current assets | $353.76M | $266.34M | $346.54M | $375.27M | $492.34M | $193.63M | $41.66M |
| Cash and equivalents | $112.28M | $69.53M | $66.39M | $59.97M | $142.75M | $28.38M | $22.89M |
| Total liabilities | $52.51M | $116.97M | $149.46M | $186.99M | $155.41M | $168.65M | $47.86M |
| Short-term debt | $2.74M | $2.45M | $2.08M | $1.77M | $1.50M | $959.00K | $655.00K |
| Shareholder equity | $346.18M | $199.52M | $253.11M | $249.48M | $344.75M | $38.60M | $7.91M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.03B | $1.07B | $435.79M | $398.69M | $210.14M | $237.89M | $274.31M | $316.49M | $352.42M | $381.45M | $406.22M | $402.57M |
| Total liabilities | $53.29M | $49.35M | $44.29M | $52.51M | $50.10M | $102.94M | $107.55M | $116.97M | $123.25M | $133.78M | $141.77M | $149.46M |
| Cash and equivalents | $86.83M | $345.56M | $157.83M | $112.28M | $58.34M | $39.27M | $58.43M | $69.53M | $53.15M | $51.57M | $61.16M | $66.39M |
| Shareholder equity | $980.17M | $1.02B | $391.51M | $346.18M | $160.03M | $134.95M | $166.76M | $199.52M | $229.17M | $247.67M | $264.45M | $253.11M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$138.89M | -$131.50M | -$117.98M | -$109.08M | -$59.53M | $70.07M | -$24.80M |
| Capital expenditures | $1.05M | $754.00K | $1.53M | $7.69M | $1.84M | $1.11M | $1.82M |
| Free cash flow | -$139.93M | -$132.25M | -$119.51M | -$116.77M | -$61.36M | $68.97M | -$26.62M |
| Share repurchases | $36.00K | $0 | $241.00K | $8.00K | N/A | N/A | N/A |
| Investing cash flow | -$40.87M | $86.13M | $41.43M | $26.40M | -$183.43M | -$145.47M | $848.00K |
| Financing cash flow | $222.50M | $47.66M | $82.41M | $1.61M | $357.32M | $80.88M | $11.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$37.14M | -$38.87M | -$44.36M | -$29.72M | -$30.95M | -$36.52M | -$41.70M | -$36.65M | -$33.39M | -$23.61M | -$37.86M | -$27.47M |
| Capital expenditures | $77.00K | $20.00K | $2.00K | $222.00K | $151.00K | $624.00K | $51.00K | $124.00K | $115.00K | $320.00K | $195.00K | $226.00K |
| Free cash flow | -$37.22M | -$38.89M | -$44.36M | -$29.94M | -$31.10M | -$37.14M | -$41.75M | -$36.77M | -$33.51M | -$23.93M | -$38.05M | -$27.69M |
Frequently Asked Questions About TNGX
What is Tango Therapeutics' annual revenue?
Tango Therapeutics reported revenue of $62.38M for the fiscal year ended Dec 31, 2025.
How fast is Tango Therapeutics' revenue growing?
Revenue was up 48.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 35.9%.
Is Tango Therapeutics profitable?
No. Tango Therapeutics reported net income of -$101.59M for the fiscal year ended Dec 31, 2025, with a net margin of -162.9%.
How much free cash flow does TNGX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$138.89M minus capital expenditures of $1.05M produced free cash flow of -$139.93M.
How much debt does Tango Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $2.74M and cash and equivalents of $112.28M.
TNGX pages: Overview, Earnings, Forecast, Financials, Competitors